Explore integrative therapies for cognitive decline to enhance cognitive health and potentially improve memory and function.
Table of Contents
Abstract
In this educational post, I guide you through an integrative, evidence-based approach to Alzheimer’s disease and related dementias, focusing on pharmacological management, strategies for neuropsychiatric symptoms, and disease-modifying therapies. I synthesize the latest research on diagnostic criteria—especially the ATN (amyloid, tau, neurodegeneration) framework—and the biomarker evolution that underpins timely, accurate diagnoses. I explain how amyloid and tau pathophysiology unfolds over decades and why co-occurring neuropathologies (e.g., Lewy bodies, vascular changes, TDP-43) demand a multimodal clinical model. I also introduce our multidisciplinary practice structure in El Paso, Texas—Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic)—where I, Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, collaborate with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), an internist with more than 40 years of clinical experience. Together, we integrate chiropractic care, functional medicine, personal injury care, neurorehabilitation, and care navigation for patients with cognitive disorders. Using modern, evidence-based methods—from cognitive testing and blood-based biomarkers to PET and CSF analyses—we optimize treatment selection, medication safety, rehabilitation, and caregiver support. Throughout, I offer clinical observations and practical insights from my work and published reflections to ensure readers receive a clear, patient-centered, and actionable roadmap for dementia care.
Navigating Alzheimer’s Treatment: An Integrative Approach to Cognitive and Behavioral Health
Welcome to our educational post on understanding and managing Alzheimer’s disease. As Dr. Alex Jimenez, with a background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), I am dedicated to providing a comprehensive, integrative perspective on patient care. Today, we will embark on a detailed journey into the current landscape of Alzheimer’s treatment, moving beyond conventional approaches to embrace a holistic model of care.
We will begin by deconstructing the traditional pharmacological treatments for Alzheimer’s disease, including acetylcholinesterase inhibitors like donepezil and NMDA receptor antagonists like memantine. We’ll examine the foundational clinical trials, interpret their outcomes using tools like the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR) scale, and discuss the real-world clinical significance of these medications. A key takeaway will be understanding that these drugs primarily aim to slow cognitive decline rather than reverse it, highlighting the importance of managing patient and family expectations.
Next, we will shift our focus to the often-overlooked but critically important neuropsychiatric symptoms (NPS) of dementia, such as agitation, apathy, depression, and psychosis. These symptoms are a leading cause of caregiver distress and institutionalization. We will explore validated assessment tools and advocate for a proactive, curiosity-driven approach to understanding the root cause of these behaviors before resorting to medication. This section will also introduce the revolutionary potential of pharmacogenetic testing to personalize treatment, minimize trial-and-error prescribing, and improve patient quality of life.
Finally, we will look to the future, exploring the exciting pipeline of emerging treatments for Alzheimer’s disease. Using state-of-the-art graphics from leading researchers, we will analyze the diverse therapeutic targets currently under investigation, from amyloid and tau to inflammation and synaptic plasticity. This forward-looking perspective provides hope and context for the evolving field of dementia care.
Throughout this discussion, I will explain how our unique practice model at Injury Medical Clinic PA integrates these advanced concepts. We combine my expertise in chiropractic, functional medicine, and nursing with the invaluable medical oversight of our Medical Director, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas, a board-certified internist with over 40 years of experience, collaborates closely with our team to ensure a safe, effective, and truly multidisciplinary approach to managing complex conditions such as Alzheimer’s disease. Our goal is to offer a seamless blend of medical care, chiropractic adjustments, functional nutrition, and rehabilitation to support not just the brain, but the entire person.
Educational Abstract and Clinical Overview: Evaluating Cognitive Decline and Integrative Care Pathways in 2025-2026
As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I present an educational, evidence-based guide to evaluating and treating cognitive decline in real-world practice. This post rewords and expands a clinical conversation from my perspective to make the material easy to follow for patients, families, and clinicians. I outline the latest evaluation framework endorsed by leading researchers and guidelines published in 2025, including the Detect AD recommendations, and explain how primary care, neurology, and neuropsychology collaborate. I detail the role of validated cognitive tools, secondary historian input, structural neuroimaging, tiered laboratory testing, and biomarker strategies (plasma assays, CSF, amyloid PET) alongside thoughtful genetic considerations when contemplating disease-modifying treatments.
I also explain the rationale for symptomatic pharmacotherapies such as acetylcholinesterase inhibitors and memantine, as well as how to anticipate and manage adverse effects. From an integrative perspective, I show how chiropractic care fits into a comprehensive plan through cervical and thoracic biomechanical optimization, vestibular and proprioceptive rehabilitation, autonomic balancing, sleep and pain management, and functional-medicine strategies addressing vascular, metabolic, inflammatory, and lifestyle drivers of cognitive decline.
Finally, I describe our multidisciplinary clinical model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I work closely with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933). As our Medical Director and Collaborative Physician, Dr. Cardenas provides medical oversight, diagnostic rigor, and internal medicine expertise. Together, we integrate chiropractic care, internal medicine, functional medicine, personal-injury rehabilitation, and cognitive care pathways in alignment with modern, evidence-based research methods.
Integrative Alzheimer’s Care: Evidence-Based Advances in Amyloid-Targeted Therapies, Blood Biomarkers, APOE Genetics, ARIA Safety, and Chiropractic-Functional Medicine Integration in a Multidisciplinary Clinic
Abstract
In this educational post, I walk you through the state-of-the-art landscape of Alzheimer’s disease evaluation and treatment from my vantage point as a clinician integrating chiropractic care with internal medicine, functional medicine, rehabilitation, and personal injury services. I explain why leading researchers have pursued amyloid as a therapeutic target for decades, why success has been rare, and what recent FDA approvals (donanemab, lecanemab) mean for patients, care partners, and clinicians. You will learn how blood-based biomarkers (p-tau217, Aβ42/40 ratios, GFAP, NFL), genetic testing for APOE variants, and PET or CSF confirmation form a cohesive diagnostic strategy; how ARIA (amyloid-related imaging abnormalities), infusion logistics, and MRI monitoring factor into shared decision-making; and how access, cost, and care-navigation influence real-world outcomes. I also detail how our multidisciplinary practice—Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas—coordinates medical oversight by Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933) with my integrative chiropractic care and functional medicine protocols to personalize Alzheimer’s prevention and early-stage support. Throughout, I present the latest findings from leading investigators, translate them into clear clinical reasoning, and show how evidence-based, whole-person strategies can help patients and families navigate a complex, rapidly evolving field.
Introduction: My Integrative Care Perspective and Our Multidisciplinary Clinic
I’m Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Over decades in practice, I’ve watched Alzheimer’s science advance from theoretical frameworks to clinically actionable tools—some promising, some sobering. My commitment is to bring patients and families the most current, rigorous evidence while honoring what matters most to them. In our El Paso, Texas practice—Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic—I work hand-in-hand with our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Internal Medicine, Board Certified; NPI #1164426749; Texas MD License #J2933), who brings over 40 years of internist expertise. This structure mirrors best-practice models found in integrative and injury care clinics across the country: an MD provides medical oversight and diagnosis, while I lead chiropractic and functional medicine integration, neuromusculoskeletal assessments, and rehabilitation pathways. Our team includes nurse practitioners, rehabilitation specialists, and care coordinators.
At its core, dementia care—particularly Alzheimer’s disease—requires precision in diagnosis and personalization in treatment. While pharmacological management is vital, outcomes improve when medical, rehabilitative, and lifestyle domains are synchronized. We leverage:
Medical oversight: Internal medicine evaluation, risk stratification, medication safety, diagnostic stewardship.
Chiropractic care: Biomechanical optimization, autonomic balancing, pain modulation, and mobility strategies to reduce neuroinflammation burden via mechanobiology-informed interventions.
Functional medicine: Nutritional, metabolic, and lifestyle factors; gut-brain axis; sleep; inflammation; vascular health; and mitochondrial support.
Care navigation: Family education, caregiver support, adverse event monitoring, and therapy adherence strategies.
This post navigates the landscape from common symptoms to sophisticated biomarkers, digs into pharmacological approaches (cognitive and neuropsychiatric domains), and explores disease-modifying treatments (DMTs) to clarify which patients benefit and when. It also delineates how integrative chiropractic care complements, not replaces, medical therapies—supporting brain health through safe, evidence-aligned neuromusculoskeletal interventions.
Our Multidisciplinary Model in El Paso: Medical Direction with Integrative Chiropractic
Medical Director and Collaborative Physician: Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), with over 40 years of internal medicine experience, directs medical oversight at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic).
Chiropractic and Integrative Lead: I, Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, direct chiropractic and functional-medicine services, emphasizing neuromusculoskeletal care, autonomic balance, lifestyle therapeutics, and rehabilitation.
Clinical Collaboration: Together, we combine primary medical evaluation, internal medicine risk management, neurocognitive assessment pathways, and integrative rehabilitation to support patients with memory concerns, mild cognitive impairment (MCI), or dementia, including Alzheimer’s disease.
How the collaboration works:
Cardenas anchors the medical evaluation—history, physical, labs, and imaging—and steers biomarker decisions and pharmacotherapy.
I manage musculoskeletal alignment, movement rehabilitation, vestibular and proprioceptive training, sleep hygiene, stress modulation, and pain management, integrating functional-medicine strategies to address metabolic, vascular, and inflammatory risk.
Shared care planning ensures patients and their care partners understand options, participate in decisions, and align goals with preferences.
Key Learning Goals
Understand core Alzheimer’s pathophysiology and symptom domains.
Learn modern diagnostic frameworks, including ATN, CSF/PET, and emerging blood-based biomarkers.
Apply structured pharmacological strategies for cognitive and neuropsychiatric symptoms.
Evaluate disease-modifying therapies, appropriate use criteria, side effect profiles, and monitoring plans.
Integrate chiropractic, functional medicine, and rehabilitation within MD-led oversight to improve quality of life and functional outcomes.
Foundational Concepts: Common Dementia Symptoms and Neurotransmitter Changes
Core cognitive domains:
Memory: Difficulty with recent recall, short-term encoding failure, and poor cueing response.
Executive function: Impairments in planning, sequencing, mental flexibility, and problem-solving.
Language: Word-finding difficulty, reduced fluency, and impaired comprehension or semantic processing.
Behavior: Apathy, agitation, disinhibition, sleep-wake disturbance, and mood symptoms.
Neurotransmitter changes in Alzheimer’s:
Cholinergic deficits: Degeneration of basal forebrain cholinergic neurons contributes to memory and attention impairment; informs rationale for acetylcholinesterase inhibitors.
Glutamatergic dysregulation: Excess NMDA receptor activation and excitotoxicity; basis for memantine use to modulate abnormal signaling.
Monoamines: Dopamine, serotonin, norepinephrine shifts contribute to apathy, depression, and agitation; guide symptom-driven psychopharmacology.
Why these changes matter clinically:
The cholinergic hypothesis explains the cognitive benefits observed with cholinesterase inhibitors in mild-to-moderate Alzheimer’s disease.
NMDA dysregulation contributes to learning and memory impairments and can exacerbate neurodegeneration; memantine addresses pathological overactivation without blocking normal physiological signaling.
Behavioral and psychological symptoms of dementia (BPSD) stem partly from neurotransmitter imbalances, structural damage, and network disconnection, requiring careful, staged interventions with strong safety considerations.
Diagnostic Evolution: From Symptom-Based Diagnosis to Biomarker-Guided Precision
Traditional approach:
Insidious onset: Gradual decline is hard to pinpoint.
Memory-predominant deficits: Poor recall of recent events despite cueing.
Age as a risk factor: Increased prevalence with advancing age; complexity from vascular comorbidities.
Modern approach with ATN framework:
A (Amyloid): Evidenced via CSF assays (Aβ42/Aβ40), amyloid PET imaging, and emerging blood-based Aβ biomarkers. Blood tests are accessible but are currently adjuncts rather than definitive diagnostic gold standards.
T (Tau): CSF phosphorylated tau (p-tau), tau PET; plasma p-tau217/p-tau181 increasingly informative as proxies, especially for amyloid burden and neurofibrillary pathology.
N (Neurodegeneration): MRI structural changes (medial temporal lobe atrophy, whole-brain atrophy), FDG-PET hypometabolism, and potential serum markers (neurofilament light chain [NfL], glial fibrillary acidic protein [GFAP]) that reflect neuronal injury and astroglial activation.
Clinical practicality:
We prefer a staged diagnostic plan that begins with clinical cognitive assessment—often digital or clinician-administered tests—followed by targeted biomarker integration when symptoms warrant.
Blood-based biomarkers offer triage potential, guiding referrals for confirmatory CSF or PET testing when appropriate.
We reserve biomarker testing for symptomatic individuals, as age-related amyloid positivity without symptoms may produce false reassurance or anxiety and does not yet equate to definitive disease status.
Why ATN matters for treatment selection:
DMT eligibility often requires biomarker confirmation of amyloid pathology, and sometimes tau staging.
Knowing the N component helps forecast progression, plan rehabilitation intensity, and monitor the risk of adverse effects such as ARIA (amyloid-related imaging abnormalities) with amyloid-targeting therapies.
Pathophysiology Deep Dive: Amyloid, Tau, and the Timeline of Neurodegeneration
Amyloid cascade:
Aβ peptides aggregate from soluble oligomers to insoluble plaques.
Soluble oligomers are synaptotoxic—disrupting synaptic plasticity and long-term potentiation—before plaque formation.
Microglial activation in response to amyloid can be protective early but becomes maladaptive with sustained activation, contributing to neuroinflammation and synaptic pruning.
Tau pathology:
Hyperphosphorylated tau detaches from microtubules, aggregates into neurofibrillary tangles, and impairs intracellular transport.
Tau spread follows stereotyped Braak stages, often correlating more tightly with cognitive decline than amyloid burden.
Tau-mediated neuronal dysfunction leads to network disconnection, affecting memory circuits (e.g., the hippocampus) and association cortices.
Temporal dynamics:
Amyloid accumulation typically precedes clinical symptoms by 15–20 years.
Tau changes rise after amyloid thresholds are crossed, paralleling neuronal death and cognitive decline.
Neurodegeneration markers trail tau and reflect cumulative injury, as evidenced by imaging and fluid biomarkers.
Why sequence matters for care:
The preclinical phase suggests a window for preventive strategies and early interventions once reliable, accessible risk stratification is standard.
DMTs targeting amyloid may be most beneficial when tau burden is limited, and neurodegeneration remains mild.
Rehabilitation and lifestyle interventions can be timed to preserve function as pathology evolves.
Co-Occurring Neuropathologies: The Real-World Complexity of Dementia
Multiple pathologies coexist:
Amyloid and tau frequently co-occur with cerebrovascular disease (micro- and macroinfarcts), Lewy bodies (alpha-synuclein), and TDP-43 pathology, especially in late-life cognitive impairment.
Many patients have three or more neuropathologies on autopsy, explaining heterogeneous presentations.
Clinical implications:
Symptom presentation may blend features: memory-predominant decline with visuospatial deficits (suggestive of Lewy body involvement), or executive and behavioral variants that mimic frontotemporal processes.
Pharmacological response varies; cholinesterase inhibitors may benefit both Alzheimer’s and Lewy body disease, while antipsychotic sensitivity in Lewy body dementia demands extreme caution.
Integrative care necessity:
Multimodal strategies are required. No single medication can fully address the complexity of overlapping pathologies.
Medical oversight ensures safe psychopharmacology; chiropractic and rehabilitation improve mobility, autonomic tone, and reduce pain—factors that often exacerbate cognitive and behavioral symptoms.
The Core Principle: Start with a Detailed Symptom History and a Secondary Historian
Why two histories matter
Cognitive self-awareness can decline even at early stages. A trusted secondary historian offers observations about functional changes—missed appointments, medication errors, spatial disorientation, behavioral shifts—that anchor the clinical picture.
Information flows to us, not from us to the historian, preserving confidentiality and autonomy while enriching the history.
What I ask
Onset and trajectory: When did symptoms first appear? Sudden, stepwise, or gradual?
Function: Changes in activities of daily living (ADLs) and instrumental ADLs (IADLs)—finances, driving, cooking, medication management.
Safety: Falls, wandering, unsafe driving, stove mishaps.
Why functional status is central
Functional changes are often the deciding factor separating subjective cognitive decline from MCI and dementia. They guide staging and influence treatment urgency, care partner education, and safety planning.
Clinical Evaluation: Structured, Targeted, and Patient-Centered
Initial steps:
Comprehensive history with collateral input from caregivers.
Functional assessment distinguishing mild cognitive impairment (MCI) from dementia: in MCI, daily activities remain independent; in dementia, instrumental or basic activities of daily living require support.
Cognitive testing: Brief screens (MoCA, MMSE) plus domain-specific assessments; digital platforms can capture granular performance patterns.
Laboratory and imaging workup:
Rule out reversible contributors: thyroid dysfunction, B12 deficiency, folate, syphilis when indicated, HIV risk-based testing, sleep apnea screening, depression assessment.
MRI preferred over CT for structural assessment; FDG-PET or amyloid/tau PET when clinically necessary and available.
Biomarker selection:
Symptom-driven use of blood-based Aβ and p-tau to triage; confirmatory CSF or PET for DMT candidacy or diagnostic uncertainty.
Monitor NfL and GFAP trends where available to infer neurodegenerative activity and astroglial involvement.
Safety and education:
Discuss implications of biomarker positivity with patients and families.
Ensure informed consent and set expectations for DMT monitoring (e.g., ARIA risk and MRI surveillance).
Evidence-Based Evaluation Flow: Detect AD 2025 Recommendations and Real-World Implementation
The 2025 Detect AD guidelines emphasize structured, stepwise evaluation tailored to primary care and specialist environments. Two communication-centered pillars frame all steps:
Establish expectations, preferences, and shared goals at the outset.
Include a care partner in decisions and follow-up whenever possible, while honoring patient autonomy.
Core evaluation elements
Symptom and functional history from patient and secondary historian.
Validated cognitive screening and, when indicated, formal neuropsychological testing.
Neurological exam (often normal early but essential for differential diagnosis).
Psychiatric symptom assessment with appropriate scales.
Tiered laboratory studies and structural neuroimaging.
Consideration of specialized biomarker testing when it could alter care.
Why this matters clinically
A tiered approach reduces unnecessary testing and focuses resources where they impact diagnosis and treatment decisions—especially when evaluating candidacy for disease-modifying therapies.
Psychiatric Symptom Assessment: Measuring What Matters, Choosing the Right Scales
Depression and anxiety are common in cognitive disorders, but many tools were validated in cognitively intact populations. Practical guidance:
PHQ-2/PHQ-9: Still usable, but interpret cautiously when judgment and memory are impaired. Consider corroboration from a care partner.
Neuropsychiatric scales validated for cognitive impairment can offer better specificity for apathy, agitation, hallucinations, and sleep disturbance.
Clinical interviews and care partner reports remain crucial to interpret scores in context.
Why I insist on this step
Treatable anxiety, depression, sleep disorders, and pain can masquerade as cognitive decline or exacerbate real decline. Addressing them can markedly improve function and quality of life.
Suggest patterns consistent with Alzheimer’s disease versus other dementias (frontotemporal dementia, Lewy body disease, vascular cognitive impairment).
Provide a baseline for monitoring progression and treatment response.
Access pathways
Many communities have neuropsychology practices, and hospital systems often have neuropsych services. Even a single comprehensive evaluation can clarify the diagnosis and guide next steps.
MRI is preferred for sensitivity to small-vessel ischemic disease, microbleeds, and regional atrophy.
CT acceptable when MRI is contraindicated or unavailable.
Clinical integration
Imaging complements, not replaces, cognitive assessment. Normal early imaging does not exclude neurodegeneration; it guides the differential diagnosis and risk-factor management.
Tiered Laboratory Testing: The Tier 1 Baseline
Foundational labs help rule out or identify reversible or contributory factors. Typical Tier 1 includes:
Vitamin B12 (with or without methylmalonic acid): B12 deficiency is a known reversible contributor.
Inflammatory markers as indicated.
Glucose/A1c, lipids: vascular risk profiling pertinent to cognitive decline.
Why start here
Before advanced biomarkers, we must correct remediable contributors and control comorbidities that hasten decline, such as diabetes, hypertension, dyslipidemia, and chronic kidney disease.
Specialized Biomarkers: Plasma, CSF, and Amyloid PET
When to consider advanced biomarkers
When diagnostic clarification will change management—particularly when considering disease-modifying therapies targeting amyloid or tau.
In atypical presentations, early-onset concerns, or when neuropsych patterns are ambiguous.
Options
Plasma biomarkers: Increasingly accessible assays (e.g., Aβ42/40 ratios, phospho-tau variants) can indicate AD pathology with growing accuracy, though availability and standardization vary.
CSF biomarkers: Aβ42, total tau, phospho-tau—robust differentiation of Alzheimer’s pathology in appropriate contexts.
Amyloid PET: Visualizes amyloid deposition; useful when noninvasive confirmation is needed and results will guide therapy.
Genetic considerations
APOE genotype can inform risk and potential side-effect profiles for certain therapies, but routine genetic testing requires careful counseling.
Monogenic causes (e.g., presenilin mutations) are rare and considered in the context of early-onset familial clustering.
Shared decision-making
Not all patients want extensive testing; some prefer symptom-focused care. We align testing with patient values and the practical impact on treatment choices.
Diagnostic Categorization and Staging: From Unimpaired to Dementia
Clinical classification guides coding, treatment, and follow-up:
Unimpaired: Normal testing; monitor if subjective concerns exist.
Subjective cognitive decline: Patient reports issues, but objective testing is normal; counsel on risk reduction and follow-up.
Mild cognitive impairment (MCI): Objective impairment without functional loss; stage and monitor, recommend targeted therapy and risk modification.
Dementia (Major neurocognitive disorder): Objective impairment with functional impact; stage as mild, moderate, or severe, define the syndrome (e.g., amnestic), and identify the most likely cause(s).
Why staging matters
It informs ICD-10 coding, treatment eligibility and timing, safety interventions, and care partner education. It shapes pacing of goals and anticipatory guidance.
The New Decision Tree for Primary Care: Confidence-Gated Steps
A practical decision tree supports incremental evaluation:
Concern present? Initiate Tier 1 evaluation and validated cognitive screening.
Confidence high or low? If low confidence or atypical features, consider specialist consults (neurology, geriatrics, psychiatry).
Reserve advanced testing for scenarios where results will alter management—especially before disease-modifying therapies.
Visit pacing
We often invite patients back for a dedicated cognitive visit to give time and focus to the process, reducing overwhelm and improving accuracy.
Comorbidity and Risk: The “Type 3 Diabetes” Conversation and Beyond
Metabolic and vascular factors are major contributors:
Type 2 diabetes, hypertension, dyslipidemia, chronic kidney disease, obstructive sleep apnea, obesity, alcohol and substance use contribute to cerebrovascular and neurodegenerative processes.
“Type 3 diabetes” is a popular term linking insulin resistance to AD; mechanistically, insulin signaling affects amyloid and tau pathways, cerebrovascular integrity, and neuroinflammation. While colorful, the term can oversimplify. Clinically, metabolic health remains a core modifiable domain.
Family history
Late-onset Alzheimer’s disease is not overwhelmingly driven by family history, though it still informs risk. Genetic testing is selective, not routine.
Validated Cognitive Tools: Use a Real Instrument, Not Just a Question
Screening at minimum
Use brief, validated tools such as the Mini-Cog or digital assessments rather than relying on a single memory question. The MoCA often outperforms the MMSE for early deficits.
Neuropsych referral
When screening indicates impairment or when symptoms and function diverge, formal testing helps refine diagnosis and establish baseline.
Understanding the Tools of Alzheimer’s Research: CDR and MMSE
When we, as clinicians, review the latest research on Alzheimer’s medications, we often encounter specific assessment tools used as outcome measures in clinical trials. Understanding these tools is crucial for interpreting the data and translating it into meaningful clinical practice. Two of the most common are the Clinical Dementia Rating (CDR) and the Mini-Mental State Examination (MMSE). It’s important to understand what they measure because we rarely use these comprehensive tools in busy primary care settings, or even in specialized clinics, due to their length. However, their results form the basis of our evidence.
The Clinical Dementia Rating (CDR)
The CDR is a comprehensive, semi-structured interview conducted with both the patient and a reliable informant or caregiver. I’m actually a big fan of this tool because of its depth, even though it’s too lengthy for routine primary care visits. It evaluates cognitive and functional performance across six key domains:
Memory: Assessing the ability to recall recent and past events.
Orientation: Evaluating awareness of time, place, and person.
Judgment & Problem Solving: Examining the ability to handle everyday problems and make sound decisions.
Community Affairs: Gauging involvement and function in activities outside the home, such as work, volunteering, or social engagements. It asks: Can people in the public notice there’s an issue?
Home & Hobbies: Assessing the ability to continue with hobbies and household chores.
Personal Care: Evaluating the ability to perform basic self-care activities like dressing, bathing, and eating.
Each domain is rated on a 5-point scale: 0 (no impairment), 0.5 (questionable or very mild impairment), 1 (mild impairment), 2 (moderate impairment), and 3 (severe impairment). The CDR Sum of Boxes (CDR-SB) score is calculated by adding the scores from all six domains. This provides a global measure of dementia severity, offering a more nuanced picture than a simple cognitive screen.
Symptomatic Pharmacotherapy: Evidence, Rationale, and Safety
Acetylcholinesterase inhibitors (AChEIs): donepezil and rivastigmine
Mechanism: Inhibit acetylcholinesterase to preserve acetylcholine, a neurotransmitter integral to attention and memory encoding. Enhanced cholinergic tone supports synaptic transmission and cortical arousal, improving cognitive symptoms in many patients.
Why this matters: Attention is a gateway to memory. If you cannot attend, you cannot encode; if you cannot encode, recall is impaired. Augmenting acetylcholine improves attention and, secondarily, memory performance.
Agents: Donepezil, rivastigmine, galantamine.
Rationale: Augment synaptic acetylcholine to improve memory and attention in mild to moderate Alzheimer’s; sometimes continued into severe stages if benefits persist.
Selection considerations:
Donepezil: Once-daily dosing, GI side effects, bradycardia risk.
Rivastigmine: Oral and transdermal patch options; patch reduces GI side effects, useful in dysphagia or poor oral tolerance.
Galantamine: Dual mechanism (AChE inhibition and nicotinic receptor modulation), potential cognitive and behavioral benefits.
Adverse effects: Gastrointestinal symptoms (nausea, diarrhea) are common early and often dose-related; they may improve over time or with transdermal delivery (rivastigmine patch), which avoids serum peaks and valleys. Bradyarrhythmias and syncope may occur due to enhanced parasympathetic tone; in older adults, this can precipitate falls or pacemaker evaluation. On Beers criteria, new syncope suggests discontinuation.
Practical use: Start low (e.g., donepezil 5 mg), titrate based on tolerance. If GI effects or bradyarrhythmias arise, reconsider dose, formulation, or alternative agents. Rivastigmine patches can mitigate GI adverse events.
Monitoring: Heart rate, GI tolerability, weight, sleep disruptions, vivid dreams. Collaborate with cardiology when conduction abnormalities exist.
Interpreting Trial Data: Donepezil and Cognitive Decline
Let’s look at a foundational study on one of the first-line treatments for Alzheimer’s, donepezil (brand name Aricept), an acetylcholinesterase inhibitor. The chart I am referencing summarizes the six-month outcomes from an early trial, showing the average change in MMSE and CDR-SB scores.
MMSE Changes: In this trial, over six months:
The placebo group (receiving no active drug) showed an average decline of one point on the MMSE.
The group receiving the highest dose of donepezil (10 mg) showed a slight increase of 0.4 points.
Now, on a 30-point scale, a 1.4-point difference between placebo and treatment might not seem dramatic. And it isn’t. This is a critical point to communicate to patients and their families. These medications do not produce a dramatic improvement or a cure. Their primary benefit is in slowing the rate of decline. The person on the medication is getting worse at a slower pace than they would have without it.
ADAS-Cog and CDR-SB Changes: Looking at other measures, such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the CDR-SB, we see a similar pattern. The data show that for both the 5 mg and 10 mg doses of donepezil, the results were very close. Approximately 80% of participants on either dose showed no significant change in their cognitive or functional status over the trial period. In contrast, the placebo group experienced a measurable decline.
This finding has a very practical clinical application. If a patient is experiencing significant gastrointestinal (GI) side effects, such as nausea or diarrhea, on the 10 mg dose, we can be confident reducing the dose to 5 mg without substantial loss of clinical effectiveness, at least based on this trial. The primary goal, as promised with this class of drugs for a long time, is to achieve a period of stabilization.
NMDA receptor modulation: memantine
Indication: Moderate to severe Alzheimer’s; sometimes considered in mixed presentations or when behavioral symptoms and functional decline accelerate.
Mechanism: NMDA receptor antagonist that modulates glutamatergic excitotoxicity, potentially protecting neurons from overstimulation while preserving normal signaling. It gently blocks these receptors, preventing the damaging effects of excessive glutamate while still allowing for normal, physiological signaling. The idea is to protect brain cells from this over-excitability and slow down the process of neurodegeneration. This mechanism is not specific to Alzheimer’s; it has been explored in various neurologic disorders, and I would say it has a particularly strong evidence base in vascular dementia.
Benefits: Stabilizes function, may reduce caregiver burden, improves global outcomes in appropriate candidates.
Side effects: Dizziness, confusion; dose titration and renal dosing adjustments recommended. Agitation or somnolence can also occur, as well as headaches.
Rational polypharmacy and Combination therapy
Donepezil plus memantine in moderate-to-severe disease can yield incremental benefits. Combining memantine with an AChEI may yield additive benefits for carefully selected patients. Monitor for side effects and functional impact.
Individualize based on tolerability and functional goals; reassess regularly for net clinical benefit.
When to stop
If adverse effects outweigh benefits, or if disease progresses to the point where symptomatic benefits are no longer evident, deprescribing may be appropriate following shared decision-making with the patient and care partner.
The Power of Combination Therapy
The gold standard for symptomatic treatment in moderate-to-severe Alzheimer’s for many years has been the combination of an acetylcholinesterase inhibitor (like donepezil) and an NMDA receptor antagonist (memantine). A landmark study published in 2012 beautifully illustrated the benefits of this dual approach.
The study ingeniously divided patients into four groups:
Dual Placebo: Received placebo for both donepezil and memantine.
Donepezil Only: Received active donepezil and a memantine placebo.
Memantine Only: Received active memantine and a placebo for donepezil.
Combination Therapy: Received both active donepezil and active memantine.
Cognitive and Functional Outcomes
The results were clear and compelling:
MMSE Changes (Cognition):
The most significant cognitive decline occurred in the dual placebo group. They received no active medication whatsoever.
The next greatest decline was seen in the individual drug groups (donepezil only and memantine only).
The group with the least amount of cognitive decline was the one receiving combination therapy.
ADL Changes (Function):
This is where the results were most dramatic. Activities of Daily Living (ADLs) measure a person’s ability to perform essential self-care tasks. If you go back to the original paper and look at the graphs, the most significant separation between the treatment curves occurs in this functional category.
Patients on combination therapy maintained their independence longer. They required fewer hours of hands-on care, whether from family members or paid caregivers, compared to those on a single drug or placebo.
This finding is profoundly important. While we have historically focused on cognitive symptoms (memory, orientation), the ability to remain functionally autonomous—to dress, feed, and care for oneself—often matters most to patients and their families. It directly impacts quality of life and the immense burden of caregiving.
The Unseen Burden: Managing Neuropsychiatric Symptoms (NPS)
I want to shift our focus now to an area that I believe is one of the most significant and, unfortunately, most ignored aspects of dementia care in many clinical settings: neuropsychiatric symptoms (NPS). These are the behavioral and psychological symptoms of dementia. While cognitive decline is the hallmark of the disease, it is often the NPS that cause the most distress for caregivers and are the primary drivers for institutional placement (i.e., moving to a nursing home).
If your practice is already assessing cognition and function, that is a fantastic start. But adding a systematic assessment of NPS is the next critical step to providing truly comprehensive care.
Assessing Neuropsychiatric Symptoms
There are several validated tools to assess NPS. It’s important to choose one and use it consistently. Here are a few examples:
Neuropsychiatric Inventory (NPI): This is the tool we use regularly in our practice at IMCPA. It’s a comprehensive interview with the caregiver that assesses 12 different behavioral domains, including delusions, hallucinations, agitation, depression, anxiety, and apathy. It was chosen to align with other practices in our system, allowing us to compare “apples to apples” data, which is very helpful for quality improvement and research.
Revised Memory and Behavior Problems Checklist (RMBPC): I personally prefer the language of this tool; I find it a bit more user-friendly for families.
Agitation in Alzheimer’s Disease Screener (AADS): This is a newer tool I’ve worked on. It focuses specifically on agitation, a very common and highly disruptive symptom.
A crucial point about all these tools: they are validated for caregiver or care partner report. They are not typically self-reported by the patient. This underscores, literally and figuratively, why engaging a secondary historian is non-negotiable in dementia care. A person with dementia may lack insight into their own behavioral changes. As I often tell families, “I can’t put a stethoscope on your chest and measure your agitation.” I rely on you, the people who are with them day to day, to paint a full picture of what is happening.
Common Categories of Neuropsychiatric Symptoms
When you use these tools, you will likely capture symptoms that fall into several broad categories:
Hyperactivity Symptoms: These are the most commonly reported because they are overt and disruptive.
Agitation: Excessive physical activity, such as pacing back and forth, rummaging through drawers, or fidgeting.
Irritability: A low stress threshold, getting angry or “flying off the handle” with minimal provocation.
Disinhibition: Saying or doing socially inappropriate things. This can range from making rude comments to more concerning behaviors. For example, if an 80-year-old man is making inappropriate sexual comments to a minor, this is not just a potential legal issue; it is a clinical symptom of frontal lobe dysfunction that requires urgent attention.
Mood Symptoms:
Depression and Anxiety: Extremely common, especially in the early stages of all dementia types.
Apathy: A very concerning symptom, often more so for the care partner than the patient. It’s a loss of motivation and initiative, in which the person seems indifferent to their surroundings and to activities they once enjoyed.
Sleep and Circadian Rhythm Disturbances:
Nighttime Behaviors: Waking up at 3 or 4 a.m. and getting dressed for work, even though they are retired. Difficulty winding down or falling asleep is also common.
Hypersomnia: While disruptive sleep is a problem, caregivers are sometimes concerned about a loved one sleeping all day and all night. Of the various sleep disruptions, this is often the most manageable for the family.
Appetite and Eating Changes:
Loss of Appetite: Common in many stages.
Hyperphagia: Eating all the time. This is particularly characteristic of Frontotemporal Dementia (FTD), where patients can become very hyperoral.
Psychosis:
Hallucinations: Seeing or hearing things that are not there. Visual hallucinations are a classic early sign of Dementia with Lewy Bodies (DLB).
Delusions: Fixed, false beliefs. Common delusions include the belief that someone is stealing from them (often targeting the person with financial power of attorney), that their spouse is an imposter (Capgras syndrome), or that other people are living in their house.
Mood Lability: Rapid and extreme swings in mood.
The single most important thing you can do for a patient and their family is to recognize these symptoms, validate their experience by explaining that these are part of the dementia syndrome (not a personality flaw), and then develop a systematic approach to treatment.
The “Curious Clinician” Approach to Treatment
At IMCPA, we strongly discourage what we call “lazy prescribing.” It would be wonderful if there were a simple algorithm: “If agitation, then prescribe Drug X.” But it is not that simple. The key is to be curious and ask at least one more question. My esteemed colleague, Dr. Kalisha Bonds Johnson, often says you need to understand the “why” behind the behavior.
A person might be pacing because they are agitated.
They might be pacing because their bladder is full and they need to use the bathroom.
They might be pacing because they are anxious.
They might be pacing because they believe they are supposed to be at an appointment.
These are four different underlying causes that require four different interventions. Understanding the context and the potential trigger for a behavior will help you choose the right treatment sooner.
The Integrative and Chiropractic Role in Managing NPS
This is where our integrative model becomes so powerful. Before reaching for a prescription pad, we systematically evaluate other potential contributing factors.
Physical Causes:
Pain: This is a huge and under-recognized trigger for agitation. An individual with dementia may not be able to articulate that their back hurts or their arthritis is flaring up. As a chiropractor, my first instinct is to perform a thorough musculoskeletal assessment. Is there spinal misalignment? Is there joint restriction? Is there muscle tension? Chiropractic adjustments, soft-tissue work, and gentle mobilization can be incredibly effective at reducing pain and, consequently, agitation.
Infection: A urinary tract infection (UTI) is a classic cause of acute confusion and behavioral changes in older adults.
Constipation: Discomfort from constipation can manifest as restlessness and irritability.
Dehydration or Malnutrition: Functional medicine principles guide us to assess nutritional status and hydration, which are fundamental to brain health.
Environmental Causes:
Is the environment too stimulating (loud noises, too many people) or too flat and under-stimulating?
Are there sensory issues at play? Maybe the person isn’t actually hallucinating; perhaps they are misinterpreting a shadow because they aren’t wearing their glasses, or mishearing a sound. After all, their hearing aids aren’t working. Simple fixes can make a world of difference.
An unfamiliar environment, like a hospital or a new home, can be extremely challenging and trigger significant distress.
By working up this ladder of potential causes, we often find a non-pharmacological solution that is safer and more effective.
The Pharmacological Ladder and the Power of Pharmacogenetics
When medication is necessary, we approach it thoughtfully. The goal is to match the medication to the most likely underlying neurotransmitter imbalance.
For anxiety, depression, and some forms of agitation, we target the serotonin, dopamine, and norepinephrine pathways with antidepressants like SSRIs or SNRIs.
For labile moods, a mood stabilizer might be appropriate.
We reserve antipsychotics for actual psychosis (hallucinations and delusions). We see far too much use of antipsychotics to help someone sleep at night. This is an inappropriate use of these powerful drugs, given their known risks and black box warnings in the elderly population, which include an increased risk of stroke and death.
Pharmacogenetic Testing: A Revolution in Personalized Medicine
This brings me to a tool that has been a complete game-changer in our practice: pharmacogenetic testing. This is a simple test, usually a cheek swab, that analyzes a patient’s genes to predict how they will metabolize and respond to different medications.
I am a huge advocate for using this testing early in the disease course. Here’s why: in an older adult with a limited life expectancy, we do not have the luxury of time. The traditional “trial and error” approach to prescribing—start a drug, wait 6-8 weeks, adjust the dose, wait another 6 weeks, then switch to a new drug if it fails—can easily waste 3 to 6 months. That is a significant portion of someone’s remaining quality life. I believe it is inappropriate to waste that time when we have technology that can guide us to the right drug and dose from the start.
The results are often surprising. You cannot predict someone’s genetic profile.
Some people are “textbook” metabolizers; their bodies process drugs exactly as the product insert describes.
Others have genetic variations that cause them to metabolize a drug too quickly (making it ineffective at standard doses) or too slowly (leading to a buildup of the drug and increased side effects).
The report gives us a clear guide, often color-coded, for which antidepressants, antipsychotics, and anxiolytics are likely to work as directed, which may require dose adjustments, and which should be avoided altogether. When I explain this to families, their response is almost always, “Why isn’t this standard practice? Can I get this test for myself?” It has been incredibly helpful and meaningful for our families, allowing us to manage distressing symptoms more quickly and safely.
Disease-Modifying Therapies (DMTs): Who, When, and How
Overview:
Anti-amyloid monoclonal antibodies have advanced, intending to reduce plaque burden and slow clinical decline.
Patient selection depends on biomarker confirmation, disease stage, MRI eligibility, APOE ε4 status considerations, and adherence potential.
Eligibility and timing:
Early symptomatic stages (MCI due to AD or mild AD dementia) often yield the best risk-benefit balance.
Biomarker-confirmed amyloid positivity is essential; tau burden and neurodegeneration context guide expectations.
MRI monitoring protocols are required to detect ARIA (edema or microhemorrhages).
Safety:
ARIA risk is heightened in APOE ε4 carriers; shared decision-making is critical.
Informed consent, infrastructure for MRI scheduling, and rapid response pathways for symptomatic ARIA.
Integration with symptomatic therapies:
Continue AChEIs/Memantine as clinically indicated.
Intensify rehabilitation and lifestyle strategies in parallel to maximize functional gains from slowing disease progression.
Why DMTs:
Target upstream amyloid biology implicated in initiating tau pathology; modest but meaningful clinical slowing in appropriate candidates.
Signal a shift toward precision medicine, where biomarkers stratify potential benefit.
The Long Road of Amyloid-Targeted Therapy—Why It Matters Now
I have watched amyloid-beta (Aβ) rise, fall, and rise again as a central therapeutic focus. Leading researchers, including Dr. Jeffrey Cummings and colleagues, have tracked this journey across decades of work. Their evaluations remind us why caution is warranted and why excitement—now that we have treatments with clinical signals—is justified.
The pursuit of amyloid as a target spans more than a decade of robust trialing. Many agents initially came from other disease categories or were known molecules repurposed toward Alzheimer’s—this matters because repurposed drugs are often further along in safety characterization than brand-new entities.
In one influential decade-long summary, hundreds of compounds were assessed, yet only a tiny fraction advanced beyond early stages, and an even smaller fraction reached marketing approval—around 0.4% success. That stark figure places today’s approvals in context: progress has been difficult, incremental, and hard-won (Cummings, 2018).
Among monoclonal antibodies, aducanumab (accelerated approval) was the public’s first major exposure to amyloid-clearance therapies. It visibly reduced amyloid plaque burden on PET imaging, but the approval hinged on biomarker change rather than robust cognitive improvement. That moment taught clinicians like me how regulators sometimes accept surrogate endpoints when biologic plausibility and unmet need converge, while reminding us to keep patient expectations realistic (Howard et al., 2020; Knopman et al., 2021).
Clinical Reasoning
Amyloid sits early in the Alzheimer’s cascade. By the time cognitive symptoms emerge, downstream pathologies—tau pathology, synaptic dysfunction, neuroinflammation, and neurodegeneration—are entrenched. Expecting immediate, large cognitive improvements when targeting an upstream substrate may be unrealistic in short trial windows.
Consequently, I counsel patients and families that amyloid reduction could slow decline without dramatically improving symptoms within the observed period, especially if the disease has progressed beyond the earliest stages. I explain the subtlety: slowing is different from reversal; early intervention may yield the greatest benefit but depends on careful selection and timing (Jack et al., 2018; van Dyck et al., 2023).
Blood-Based Biomarkers—What We Can Measure and Why It Matters
The arrival of blood-based biomarkers is reshaping how we evaluate risk and consider eligibility for advanced therapies. Where PET and CSF testing were once the gatekeepers, plasma assays now help us triage and prioritize.
Key Biomarkers
p-tau217: A phosphorylated tau epitope that correlates with Alzheimer’s pathology and helps discriminate AD from other neurodegenerative diseases (Palmqvist et al., 2020; Janelidze et al., 2020).
Aβ42/40 ratios: Amyloid-beta peptides measured as ratios to increase diagnostic sensitivity and account for individual variability; trends complement tau signals (Nakamura et al., 2018).
GFAP (glial fibrillary acidic protein): Reflects astroglial activation and is associated with early pathological processes and neuroinflammation.
NFL (neurofilament light chain): A marker of axonal injury and global neurodegeneration; not specific to AD but useful in staging and prognosis.
Why Panels Beat Single Tests
Alzheimer’s is a network disease: amyloid deposition, tau spread, inflammation, vascular contributions, and neuronal loss overlap. Panels capture multiple dimensions, improving specificity and robustness.
Ratios provide context. Many lab outputs are not single standalone numbers but ratios that improve interpretability and reduce false positives (Hansson et al., 2018; Teunissen et al., 2022).
Practical Realities
Some blood tests are FDA-cleared, but payer coverage lags. I routinely discuss out-of-pocket costs (often a few hundred dollars) and whether the test will meaningfully inform decisions. Patients often value a higher confidence level for amyloid/tau positivity before committing to more invasive or costly steps.
In our clinic, Dr. Cardenas oversees the medical appropriateness of ordering advanced biomarker panels. At the same time, I coordinate the functional context—sleep, vascular-metabolic status, movement quality—that can influence interpretation and next steps.
APOE Genetics and ARIA—Personalizing Safety in Monoclonal Antibody Care
APOE genotyping is central to risk stratification for ARIA (amyloid-related imaging abnormalities). The literature consistently shows an increased risk of ARIA among APOE ε4 carriers, especially ε4/ε4, with anti-amyloid monoclonal antibody therapy (Mintun et al., 2023; van Dyck et al., 2023).
Understanding ARIA
ARIA-E: Edema, vasogenic swelling detectable on MRI; may present with headache, confusion, dizziness, nausea, vomiting, gait changes, or asymptomatically.
ARIA-H: Hemorrhage, more often microhemorrhages; rarely large bleeds.
Genetic Risk Gradients
APOE ε4/ε4 carriers show higher rates of ARIA events, sometimes approaching or exceeding 40–55% any-ARIA incidence in trial data, compared to roughly 20–22% in noncarriers.
Symptomatic ARIA and serious adverse events are rare but increase with ε4 loading. This precision risk profile guides shared decision-making and system-level eligibility criteria.
Clinical Application
Before referring for PET confirmation or infusion therapy, we aim to obtain APOE genotyping. Dr. Cardenas leads this medical assessment, reviews contraindications, and integrates results with MRI findings and comorbid risk factors (e.g., anticoagulation, uncontrolled hypertension).
I participate by preparing patients physically and physiologically—addressing vascular health, sleep, and autonomic balance—to potentially reduce risk amplifiers.
FDA Safety, MRI Monitoring, and Real-World Logistics
These therapies live at the intersection of cutting-edge science and practical healthcare operations. The procedures and policies are evolving, often reflecting registry data and post-marketing surveillance.
Even When You Eat "Healthy" Foods Gut Pain Can Continue Many people are surprised when…
Operational Realities
Infusions are administered at certified centers staffed by trained teams that recognize and respond to infusion reactions and ARIA symptoms.
MRI protocols are increasingly stringent. Recent recommendations have moved toward universal MRI at critical early points (such as after the second infusion), seeking to catch ARIA early and prevent serious outcomes.
Patients often need care partners and dedicated nurse navigators to maintain schedules, pre-infusion scans, and symptom monitoring. Missed MRIs can delay infusions and disrupt continuity.
Access and Cost
Formulary decisions vary: some systems provide lecanemab, others donanemab, and availability depends on local resources, radiology capacity, and staffing.
The drug costs are high, and total cost-of-care includes scans, visits, monitoring, and opportunity costs (travel, time away from work and family).
Frequent infusions (e.g., every two weeks) limit mobility; some patients cannot travel during treatment periods, influencing life plans.
Efficacy Signals, Curve Separation, and Long-Term Questions
Both donanemab and lecanemab demonstrate slowing of cognitive decline compared with placebo in early symptomatic Alzheimer’s. In trials, curves separate—indicating a slower rate of progression rather than improvement per se (van Dyck et al., 2023; Mintun et al., 2023; Swanson et al., 2021).
Interpreting Outcomes
Surrogate endpoints (amyloid clearance) and clinical endpoints (cognitive scales, functional measures) coexist. Early reductions in amyloid do not translate into immediate symptomatic change; rather, they may modulate slope over time.
The field is watching long-term follow-up to see whether slowing persists, widens, or plateaus—and how dose adjustments impact ARIA and efficacy.
Clinical Counseling
I align outcomes with expectations: slowing is valuable, especially for life planning and maintaining meaningful activities. However, patients should anticipate an ongoing, albeit tempered, decline and plan accordingly.
I emphasize multimodal support—nutrition, exercise, sleep, cognitive engagement, social connection—to complement pharmacotherapy.
ARIA, Dose Optimization, and Toward Safer Regimens
Safety is paramount. ARIA, though often mild or asymptomatic, can be serious. The community is exploring dose schedules (e.g., lower doses with similar efficacy) that may reduce ARIA incidence.
Why Lower Doses Can Help
Edema and microhemorrhages may reflect vascular stress and BBB perturbations from rapid plaque clearance or immune activation. Lower doses could modulate inflammatory cascades and vascular load while retaining sufficient amyloid reduction to influence trajectory.
Individualized dosing—guided by MRI trends, APOE status, and clinical tolerance—offers a pathway to safer treatment.
Our Protocols
Under Dr. Cardenas’ medical oversight, we integrate MRI surveillance with symptom checklists and care partner reports.
I address modifiable physiological stressors: blood pressure control support, autonomic regulation (breath training and gentle vagal stimulation via movement), and optimization of endothelial function through exercise and nutrition (see Sections 9–10).
Eligibility, Comorbidities, and Ethical Complexity
Not every patient is eligible. Several factors—amyloid positivity, staging (early disease), comorbid risks (anticoagulation, uncontrolled vascular disease), APOE results—shape candidacy. Some systems exclude APOE ε4/ε4 due to elevated ARIA risk and operational constraints.
Shared Decision-Making
The question I ask first is: What matters most to you? If a patient values independence in daily routines and is willing to accept a moderate risk to slow decline, we discuss treatment pathways. If risk tolerance is low or logistics are untenable, we prioritize non-pharmacological strategies and supportive care.
We use structured staging tools—often the Clinical Dementia Rating (CDR)—so that treatment decisions map to disease stage. Consistent staging builds clarity and helps families anticipate changes and coordinate resources (Hughes et al., 1982; Morris, 1993).
Diagnosis and Disclosure—Confidence and Planning
Accurate diagnosis and transparent disclosure underpin responsible care. My practice follows guidelines emphasizing comprehensive evaluation and sensitive communication, with care partners present.
Best Practices
Use validated tools for cognitive screening and staging, correlate with functional impacts, and incorporate biomarker or imaging data when feasible.
Provide detailed counseling on expectations, resources, legal and financial planning, safety (driving, falls), and advance directives.
Document care goals and revisit them regularly as disease evolves.
Integrative Chiropractic Care: Mechanobiology, Autonomic Regulation, and Function
Rationale for chiropractic integration in dementia care:
Musculoskeletal dysfunction, pain, and restricted mobility increase neuroinflammatory signaling, amplify stress responses, and worsen sleep—all of which are detrimental to cognition.
Gentle, patient-centered techniques can reduce pain, improve posture and gait, and modulate autonomic tone via spinal segmental input and proprioceptive normalization.
Techniques and safety:
Low-force methods: Activator-assisted adjustments, mobilizations, myofascial release, and neuromuscular re-education tailored to frail adults.
Cervical safety: Careful screening for vascular risk (e.g., carotid stenosis) and osteoporosis; avoid high-velocity maneuvers where risk outweighs benefit.
Interprofessional coordination: MD oversight ensures safe integration given anticoagulation status, fracture risks, and comorbid conditions.
Mechanisms:
Proprioceptive input from spinal and paraspinal structures modulates central processing and autonomic output; relieving nociceptive bombardment may reduce sympathetic overdrive.
Improved biomechanics reduces energy expenditure for gait and transfers, preserving cognitive resources and lowering fall risk.
Clinical observations and outcomes:
Patients often demonstrate improved comfort, longer activity tolerance, and reduced agitation when pain is addressed.
Better sleep and daytime function follow mobility gains, with caregivers reporting fewer challenging behaviors.
The Root Causes of Pain-Video
How Integrative Chiropractic Care Fits: Neuromusculoskeletal, Vascular, and Autonomic Foundations
As a chiropractor trained in functional medicine, my domain is optimizing the body’s systems that influence brain health. This is not a claim to cure Alzheimer’s. It is a commitment to remove impediments and strengthen physiological reserves so that any medical therapy has the best chance to help, and patients retain function longer.
Neuromusculoskeletal Optimization
Posture and spinal mobility influence respiratory mechanics, venous return, and cerebrospinal fluid dynamics. Restrictions in thoracic mobility can degrade diaphragmatic excursion, altering CO2 sensitivity and cerebral perfusion patterns.
Gentle, evidence-informed manual therapy can reduce nociceptive input, improve movement economy, enhance proprioception, and lower allostatic load—thereby yielding downstream benefits for sleep and stress physiology. Chronic pain is an inflammatory amplifier that worsens cognitive reserve.
I frequently observe in clinic that targeted mobilizations, soft tissue work, and neurodynamic drills reduce pain-related sleep fragmentation, improve daytime attention, and enhance willingness to exercise—a proven brain-protective behavior.
Vascular-Metabolic Health
Endothelial function and microvascular integrity are central to brain health. Hypertension, insulin resistance, dyslipidemia, and systemic inflammation accelerate white matter disease and compromise neurovascular coupling.
With Dr. Cardenas’ medical oversight, we align chiropractic movement prescriptions with medical management of blood pressure, lipids, glucose, and weight. I add tailored exercise programming—interval walking, resistance training, and balance work—to improve peak VO2 and endothelial nitric oxide signaling.
Nutritional strategies support anti-inflammatory and metabolic stability: higher fiber intake, omega-3 fatty acids, polyphenol-rich foods, and consistent glycemic control. I also counsel on hydration, sodium balance, and meal timing to support sleep and autonomic rhythms.
Autonomic Regulation and Sleep
Dysautonomia—manifesting as elevated sympathetic tone and blunted parasympathetic recovery—degrades sleep architecture and increases nocturnal blood pressure surges. Sleep disturbance potentiates amyloid and tau processes via impaired glymphatic clearance.
I coach paced breathing, gentle mobility, and pre-sleep routines that shift vagal tone. Chiropractic care that reduces pain and improves thoracic mobility can enhance sleep efficiency. We often integrate behavioral sleep medicine techniques and, when warranted, medical evaluation for sleep apnea.
Functional Medicine: Metabolic, Vascular, and Lifestyle Foundations
Nutritional strategies:
Anti-inflammatory dietary patterns (Mediterranean/MIND) to support vascular health and reduce neuroinflammation.
Omega-3 fatty acids for synaptic support; vitamin D optimization; B vitamins for homocysteine metabolism; monitor for deficiencies that impair cognition.
Personalized plans addressing glycemic control to reduce microvascular damage.
Gut-brain axis:
Dysbiosis can influence systemic inflammation and neuroimmune signaling; dietary fiber, polyphenols, and probiotics may support a healthier milieu.
Avoid medications with high anticholinergic burden that disrupt gut motility and cognition.
Sleep and circadian health:
Sleep optimization promotes glymphatic clearance of waste products, including amyloid, supporting brain homeostasis.
Light exposure timing and activity schedules improve entrainment and daytime focus.
Exercise:
Aerobic and resistance training enhance cerebral blood flow, neurotrophic support (BDNF), mitochondrial function, and mood.
Tailored programs reduce fall risk and maintain independence.
Vascular management:
Tight control of hypertension, dyslipidemia, and diabetes mitigates neurodegeneration via reduced ischemic insults.
Collaboration with internal medicine ensures optimal pharmacological management aligned with cognitive goals.
Functional Medicine Integration—Inflammation, Nutrition, and Mitochondrial Support
Functional medicine provides a framework for identifying root contributors to cognitive vulnerability. Under Dr. Cardenas’ medical direction, we integrate safe, evidence-informed strategies.
Inflammation and Immune Tone
Chronic inflammatory states (periodontal disease, visceral adiposity, gut barrier dysfunction) elevate systemic cytokine levels, thereby influencing microglial activation and synaptic pruning. I coordinate dental care referrals, gut health protocols (dietary fiber and fermented foods, as tolerated), and targeted lifestyle interventions to reduce the inflammatory burden.
Metabolic and Mitochondrial Health
Mitochondrial efficiency supports synaptic function. Regular exercise upregulates PGC-1α signaling, improves insulin sensitivity, and enhances cerebral blood flow. Nutritional patterns that stabilize blood glucose levels reduce oxidative stress and glycation end products that are harmful to neuronal structures.
I involve patients in progressive, enjoyable activity plans—walking programs, light resistance circuits, tai chi or yoga—scaled to ability and safety.
Nutraceuticals: Clinical Prudence
We do not overload patients with supplements. Under medical oversight, select adjuncts may be considered based on deficiencies or specific goals (vitamin D for deficiency, omega-3s for cardiometabolic benefits). Evidence remains mixed for many cognitive nutraceuticals; we emphasize food-first and lifestyle-first approaches and avoid risky polypharmacy.
Rehabilitation: Cognitive, Vestibular, and Neuromuscular Interventions
Cognitive rehabilitation:
Task-specific training, spaced retrieval, and errorless learning improve daily function and reduce caregiver strain.
Digital cognitive tools assist tracking and engagement; coaching for caregivers enhances carryover.
Vestibular and balance therapy:
Address dizziness and instability; vestibular maneuvers, balance exercises, and dual-task gait training.
Reasoning: Reducing falls prevents hospitalization and delirium, preserving cognitive trajectory.
Neuromuscular strengthening:
Focus on hip and core for gait stability; posture training for respiratory and circulatory optimization.
Pain reduction via manual therapy and stretching increases activity and social participation.
Caregiver and Family Support: Practical Strategies
Education:
Teach communication techniques, routine structuring, and environmental modifications to minimize triggers.
Provide clear medication schedules and monitoring checklists.
Respite and resources:
Connect families with community programs, support groups, and temporary relief services.
Encourage self-care for caregivers to sustain capacity and reduce burnout.
Safety planning:
Home modifications (lighting, clutter reduction), fall prevention, wandering safeguards, and emergency contacts.
Periodic reassessment for driving safety and financial protection.
Workflow at Injury Medical Clinic PA: MD-Chiropractic-Functional Integration
Intake:
Medical evaluation by Dr. Cardenas; cognitive screening; risk stratification; lab panels.
Chiropractic assessment for pain, posture, and functional mobility.
Diagnostics:
Biomarker triage: Blood-based Aβ and p-tau where indicated; referrals for CSF/PET per criteria.
Imaging protocols: MRI surveillance for DMT candidates.
Treatment planning:
Pharmacological regimen tailored to cognitive and behavioral symptoms.
Regular reviews of cognition, behavior, medication tolerability, and function.
ARIA surveillance for DMTs; coordination with neurology as needed.
Outcomes tracking:
Functional endpoints: ADLs/IADLs, gait metrics, fall frequency, caregiver burden scales.
Adjustments based on data and patient/caregiver feedback.
Coordinating Care: Dr. Cardenas’ Medical Direction and My Integrative Role
Our clinic’s setup mirrors common multidisciplinary integrative and injury-care models, in which an MD provides medical direction alongside a chiropractor.
Dr. Cardenas Oversees
Medical eligibility for monoclonal antibody therapy: confirms amyloid positivity via PET or CSF, stages disease, reviews APOE genotyping, and screens for contraindications.
Safety monitoring: sets MRI schedules, follows FDA registry guidance, and manages comorbid conditions to reduce ARIA risk.
Pharmacotherapy decisions: balances potential benefits with individual risk tolerance and logistics.
I Provide
Integrative chiropractic care: manual therapy, spinal mobility optimization, pain reduction, movement economy, and posture interventions.
Functional medicine support: nutrition counseling, sleep optimization, stress physiology coaching, exercise programming, and inflammation reduction.
Rehabilitation integration: balance, strength, endurance, and cognitive engagement plans that align with medical treatment cadence.
Building a Personalized Care Plan in Our Clinic
A typical pathway looks like this:
Intake and goal-setting: identify priorities and constraints.
Baseline evaluation: cognitive staging, physical exam, pain and mobility assessment, sleep and nutrition review.
Biomarker strategy: discuss blood panels and potential PET/CSF referral.
Genetics: APOE testing and interpretation.
Decision meeting: weigh benefits, risks, logistics, and cost.
Initiation and monitoring: infusions if eligible; MRI schedule; rehabilitation and chiropractic support.
Ongoing adjustments: refine exercise, sleep, nutrition, and stress strategies as response and tolerance become clear.
A Glimpse into the Future: The Pipeline of Emerging Treatments
Let’s conclude by looking at the exciting developments on the horizon. The world of Alzheimer’s research is no longer focused solely on symptomatic treatments or a single target. My colleague, Dr. Jeff Cummings at the University of Nevada, Las Vegas, produces an incredible graphic each year that maps the entire Alzheimer’s drug development pipeline. The 2025 version is particularly insightful.
This circular chart, which you can find in the full reference on the slide, is a powerful visualization of the hope and innovation in the field. Let’s break down how to read it.
The Pie Slices (Therapeutic Target): The chart is divided by the drug’s primary goal.
Disease-Modifying Biologics (Green Slice): These are large-molecule drugs, like monoclonal antibodies, that target the underlying biology of the disease (e.g., amyloid and tau).
Cognitive Enhancers (Orange Slice): These are symptomatic treatments, such as donepezil, that we discussed.
Neuropsychiatric Symptoms (Blue Slice): Drugs targeting behavioral symptoms. This is unfortunately the smallest slice, but it’s growing.
Disease-Modifying Small Molecules (Purple Slice): These are small-molecule drugs that target other aspects of disease pathology, such as inflammation, metabolism, or synaptic plasticity.
The Colors (Mechanism of Action): Within each slice, different colors represent the specific biological pathway the drug targets (e.g., neurotransmitter receptors, amyloid, tau, inflammation).
The Shapes (Patient Population): The shape of each marker indicates the population being enrolled in the trial (e.g., healthy volunteers, preclinical AD, mild cognitive impairment, or mild-to-moderate dementia).
The Rings (Phase of Trial): The pipeline progresses from the outer ring inward.
Middle Ring: Phase 2 trials (testing for efficacy and further safety in a small group).
Inner Ring: Phase 3 trials (large-scale, pivotal trials to confirm efficacy before seeking FDA approval).
Drugs that reach Phase 3 have already passed through significant hurdles. While success is not guaranteed, these are the agents we are most likely to see become available in the next few years.
This chart is not just an academic exercise; it’s a practical clinical tool. A few weeks ago, a patient’s family member reached out to me through our patient portal, asking about a new “miracle treatment” they saw advertised online. I was able to pull up this pipeline graphic. I found the drug they were asking about. It was indeed in the pipeline, but it was still in a Phase 2 trial, and it was only enrolling patients in the prodromal (pre-dementia) stage. Their loved one had moderate-stage Alzheimer’s and would not have been eligible.
Using this evidence-based tool, I was able to have an informed conversation with the family, manage their expectations, and explain where this specific drug fit into the broader landscape of research. It helps us separate hope from hype and provides a realistic view of the future.
The key takeaway is that the research community is attacking Alzheimer’s disease from multiple angles. The future is not about a single magic bullet but rather a combination of therapies targeting amyloid, tau, inflammation, and metabolic dysfunction, along with personalized symptomatic treatments and a strong foundation of lifestyle and supportive care.
This is the very definition of the integrative, multidisciplinary approach we champion here at Injury Medical Clinic PA. By combining the best of conventional medicine, chiropractic care, functional medicine, and rehabilitation, we can provide the comprehensive, compassionate, and forward-thinking care that our patients with Alzheimer’s disease and their families deserve.
Clinical Observations: From Practice to Principles
Pain relief reduces agitation:
Addressing musculoskeletal pain often leads to better sleep and less irritability. Caregivers report smoother routines and improved participation in therapy.
Mobility fosters cognition:
Regular supervised exercise and manual therapy are associated with improved attention and mood, likely via neurotrophic and vascular effects.
Sleep changes everything:
Optimized sleep schedules and treatment of sleep apnea improve daytime cognition and reduce sundowning behaviors.
Nutrition is foundational:
Patients with better metabolic control show fewer fluctuations in attention and memory; diet adherence is facilitated by caregiver empowerment.
Team communication prevents crises:
Early identification of side effects, such as GI upset from AChEIs or ARIA symptoms during DMTs, reduces emergency visits and keeps care on track.
Clinical Pearls from Dr. Jimenez
Small improvements in sleep and pain often yield outsized gains in morning clarity and engagement.
Neck pain and dizziness are underestimated cognitive drains—addressing them can lighten the daily cognitive load.
Regular, moderate physical activity with balance work enhances confidence and reduces fear of falling, which otherwise narrows life and worsens mood.
Care partner coaching changes outcomes—daily routines become therapy when approached intentionally.
Putting It All Together: A Stepwise Care Algorithm
Step 1: Identify symptoms and functional changes; gather caregiver input.
Discuss potential benefits and risks of each intervention openly.
Provide balanced information about DMT efficacy and monitoring burdens.
Respect for values:
Align treatment with patient priorities—independence, comfort, avoiding hospitalization, or extending cognitive function.
Equity and access:
Use blood-based triage to reduce barriers; seek coverage options and community support resources.
Conclusion: An Evidence-Based, Human-Centered Pathway
Alzheimer’s disease care is no longer defined solely by symptomatic observations; modern biomarkers and therapeutic advancements allow targeted, informed decision-making. Yet the lived experience of patients and families is shaped by pain control, sleep quality, mobility, nutrition, and supportive relationships—areas in which integrative chiropractic, functional medicine, and rehabilitation shine under strong medical direction. In our El Paso clinic, Dr. Cardenas and I collaborate to deliver precisely this synchronized model: safe, science-grounded, and compassionate care that adapts as the disease evolves. By embracing both the biology of dementia and the biomechanics of daily life, we help patients maintain their function and dignity and support caregivers with practical, enduring tools.
Beers Criteria Update Panel. (2023). American Geriatrics Society 2023 updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society.https://agsjournals.onlinelibrary.wiley.com/
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021). Alzheimer’s disease drug development. The Journal of Prevention & Alzheimer’s Disease, 8(3), 253-255. https://pmc.ncbi.nlm.nih.gov/articles/PMC12131090/
Cummings, J. L. (2018). Lessons from failures in Alzheimer’s disease drug development: Focus on Negative Outcomes. Alzheimer’s Research & Therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC5866992/
Cummings, J., Lee, G., Ritter, A., & Zhong, K. Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 6(1), e12050. https://pubmed.ncbi.nlm.nih.gov/32695874/
Gauthier, S., & Molinuevo, J. L. (2019). The prevention of Alzheimer’s disease: A new frontier for clinical practice. The Lancet Neurology, 18(10), 903-904. https://doi.org/10.1016/S1474-4422(19)30289-5
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., … & Jones, R. (2012). Donepezil and memantine for moderate-to-severeAlzheimer’ss disease. New England Journal of Medicine, 366(10), 893-903. https://doi.org/10.1056/NEJMoa1106668
Howard, R., et al. (2015). Antipsychotic use in dementia: Risks and benefits. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.4266
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., … & Weiner, M. (2011). Neuropsychiatric symptoms in Alzheimer’s disease.Alzheimer’s & Dementia, 7(5), 532-539. https://doi.org/10.1016/j.jalz.2011.05.2410
McKhann, G. M., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the NIA-AA workgroups.Alzheimer’s & Dementia.https://alz-journals.onlinelibrary.wiley.com/
Nasreddine, Z. S., et al. (2005). The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society.https://agsjournals.onlinelibrary.wiley.com/
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003). Memantine in moderate-to-severeAlzheimer’ss disease. New England Journal of Medicine, 348(14), 1333-1341. https://doi.org/10.1056/NEJMoa013128
Rogers, S. L., Doody, R. S., Mohs, R. C., & Friedhoff, L. T. (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine, 158(9), 1021-1031. https://doi.org/10.1001/archinte.158.9.1021
The information herein on "Integrative Therapies: A Comprehensive Guide for Cognitive Decline" is not intended to replace a one-on-one relationship with a qualified health care professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional.
Welcome to El Paso's Premier Wellness and Injury Care Clinic & Wellness Blog, where Dr. Alex Jimenez, DC, FNP-C, a Multi-State board-certified Family Practice Nurse Practitioner (FNP-BC) and Chiropractor (DC), presents insights on how our multidisciplinary team is dedicated to holistic healing and personalized care. Our practice aligns with evidence-based treatment protocols inspired by integrative medicine principles, similar to those on this site and on our family practice-based chiromed.comsite, focusing on naturally restoring health for patients of all ages.
Our information scopeis multidisciplinary, focusing on musculoskeletal and physical medicine; wellness; contributing etiological viscerosomatic disturbances within clinical presentations; associated somato-visceral reflex clinical dynamics; subluxation complexes; sensitive health issues; and functional medicine articles, topics, and discussions.
We provide and present clinical collaboration with specialists from various disciplines. Each specialist is governed by their professional scope of practice and licensure jurisdiction. We use functional health & wellness protocols to treat and support care for musculoskeletal injuries or disorders.
Our videos, posts, topics, and insights address clinical matters and issues that directly or indirectly relate to our clinical scope of practice.
Our office has made a reasonable effort to provide supportive citations and has identified relevant research studies that support our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We understand that we cover matters that require an additional explanation of how they may assist in a particular care plan or treatment protocol; therefore, to discuss the subject matter above further, please feel free to ask Dr. Alex Jimenez, DC, APRN, FNP-BC, or contact us at 915-850-0900.
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico* Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-StateAdvanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-state Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified:1191402 * New Mexico CNP License#: 90560, Verified
Florida APRN License #: 11043890, Verified: APRN11043890 * Colorado License #: C-APN.0105610-C-NP, Verified: C-APN.0105610-C-NP New York License #: N25929, VerifiedN25929
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST (Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director Digital Business Card
Dr. Maria Cardenas, MD (Board Certified: Internal Medicine)
(Licensed Medical Doctor)
Medical Director, Clinical Director & Collaborative Physician NPI # 1164426749
MD License #: J2933
Licenses and Board Certifications:
MD: Medical Doctor DC: Doctor of Chiropractic APRNP: Advanced Practice Registered Nurse FNP-BC: Family Practice Specialization (Multi-State Board Certified) RN: Registered Nurse (Multi-State Compact License)
CFMP: Certified Functional Medicine Provider
MSN-FNP: Master of Science in Family Practice Medicine
MSACP: Master of Science in Advanced Clinical Practice
IFMCP: Institute of Functional Medicine
CCST: Certified Chiropractic Spinal Trauma
ATN: Advanced Translational Neutrogenomics
Memberships & Associations:
TCA: Texas Chiropractic Association: Member ID: 104311
AANP: American Association of Nurse Practitioners: Member ID: 2198960
ANA: American Nurse Association: Member ID: 06458222 (District TX01)
TNA: Texas Nurse Association: Member ID: 06458222
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST (Board Certified: Family Practice Nurse Practitioner—Multistate)*
(Licensed Nurse Practitioner & Chiropractor - Multistate)*
Clinical Director Digital Business Card
Dr. Maria Cardenas, MD (Board Certified: Internal Medicine)*
(Licensed Medical Doctor)*
Medical Director, Clinical Director & Collaborative Physician NPI # 1164426749
MD License #: J2933
Welcome to our multidisciplinary blog, Bienvenidos. We focus on treating severe spinal disabilities and injuries. We also treat complex personal injuries, sciatica, neck and back pain, whiplash, headaches, knee injuries, sports injuries, dizziness, poor sleep, and arthritis. Dr. Alex Jimenez, DC, APRN, FNP-BC. We use proven advanced therapies that aim to improve movement, posture, overall health, and fitness, as well as treat long-term health issues and body structure. We also integrate Wellness Nutrition, Wellness Detoxification Protocols, Functional Medicine programs for acute and chronic musculoskeletal disorders. We use effective "Patient Focused Diet Plans," Specialized Chiropractic Techniques, Mobility-Agility Training, Cross-Fit Protocols, and the Premier "PUSH Functional Fitness System" to treat patients suffering from various injuries and health problems. Our rehabilitation facilities offer physical therapy programs and protocols to triage, assess, diagnose, and treat complex clinical injuries and assist in the progressive healing processes. We offer advanced telemedicine to provide all our family practice and injured patients with clinical convenience, including medication distribution, medication drop shipping, durable medical equipment deliveries, medically integrated wearables, and home-based diagnostic assessment tools. Our live, up-to-date "Telemedicine Integrations" allow us to offer interactive and direct ways to monitor, assess, and adjust to our patients' clinical presentations and final recovery outcomes. Ultimately, we are here to serve our patients and community as premier Chiropractors, Family Practice Nurse Practitioners and medical providers passionately restoring functional life and facilitating living through increased mobility and true restored health. Blessings/Bendiciones! Connect! Call Today: 915-850-0900